Kornimate/medical-research-clean huggingface dataset:
effectiveness of serum leucine-rich alpha-2 glycoprotein levels on ibd

Conditions: LRG Levels

Summary: we attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (lrg) levels and endoscopic activity in patients with possible ulcerative colitis (uc) or crohn's disease (cd) to determine whether lrg was a predicting marker for uc or cd.

serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. serum sampling and colonoscopy with histology were performed within 7 days.the disease activity of uc and cd patients was evaluated by the mayo score and crohn disease activity index (cdai), respectively. the mayo endoscopy score was evaluated. uc patients whose mayo endoscopy score was 2 or 3 were divided into the active uc group. cd patients whose cdai \>150 were divided into the active cd group.

Eligibility criteria:
inclusion criteria: * patients whom possible uc or crohn disease was suspected exclusion criteria: * other autoimmune diseases * acute or chronic renal failure * chronic heart diseases * liver cirrhosis * cancer * acute or chronic infections * ischemic colitis * infectious colitis
effects of shenkang decoction on creatinine and blood urea nitrogen in chronic renal failure hemodialysis patients

Conditions: Chronic Renal Failure; Hemodialysis

Summary: to explore the clinical effect of shenkang decoction in chronic renal failure (crf) patients with hemodialysis (hd).


Eligibility criteria:
inclusion criteria: * the diagnosis of western medicine meets the diagnostic criteria of chronic kidney failure in internal medicine * the diagnosis of tcm meets the diagnostic criteria of the disease in the guiding principles for clinical research of new chinese medicine. * the patient is over 18 years old, * can think independently and have civil conduct, * strictly follow the doctor's advice, * maintain stable condition and regular hd treatment. exclusion criteria: * patients with hd time of no more than three months, severe uncontrolled infection, other malignant diseases, heart, liver, brain, and digestive system dysfunction, mental diseases such as dementia or depression; * contraindications to hd or contraindications to the study (shock or systolic blood pressure below 80mm/hg, severe bleeding or a tendency to bleed, serious infection such as sepsis, or a blood-borne infection, advanced tumor, extremely debilitating or not cooperating with doctor) * drug allergy, chronic use of glucocorticoids, and immunosuppressants. * women during pregnancy or lactation.
raspberries and postprandial metabolism

Conditions: Type 2 Diabetes Mellitus

Summary: raspberries are high in several phytochemicals, vitamin c and b vitamins and have been shown to be potent antioxidants and anti-inflammatory agents. however, human interventional studies reporting the effects of raspberries in obesity, t2dm and associated oxidative stress and inflammation are limited. aims, objectives and methods: aim 1: to assess the effects of raspberries in postprandial glycemia and lipemia following a high-fat fast-food style meal challenge versus control group objectives: to execute this aim, the investigators will conduct analyses of serum glucose, insulin and lipids (total cholesterol, ldl-cholesterol, triglycerides, vldl-cholesterol and hdl-cholesterol) at fasting (baseline) and at postprandial 1,2,4 hours of high-fat, fast food style breakfast consumption. the investigators will also calculate homoeostasis model assessment of insulin resistance (homa-ir) at these time points using serum glucose and insulin values. aim 2: to assess the effects of raspberries in postprandial vascular functions (blood pressure and artery elasticity) and inflammation following a high-fat fast food style meal challenge versus control group objectives: to execute this aim, the investigators will measure c-reactive protein (crp) and the following parameters of vascular function associated with cvd at fasting (baseline) and at postprandial 1,2,4 hours of high-fat, fast food style breakfast consumption: * systolic blood pressure and diastolic blood pressure * large artery elasticity index and small artery elasticity index * systemic vascular resistance


Eligibility criteria:
inclusion criteria: * type 2 diabetes exclusion criteria: * not having type 2 diabetes
postural management of hyperkyphosis in cardiac rehab patients

Conditions: Hyperkyphosis

Summary: the goal of this clinical trial is to evaluate the efficacy of a home-based exercise program in managing hyperkyphosis, and its impact on physical performance and pulmonary function among cardiac rehabilitation patients. the primary research question is: can a home-based kyphosis-specific exercise program reduce thoracic hyperkyphosis and improve physical ability in cardiac patients undergoing cardiac rehabilitation? the study will consist of three groups: 1) hyperkyphotic participants undergoing a 12-week exercise program at home, alongside a cardiac rehabilitation exercise program, 2) hyperkyphotic participants solely undergoing cardiac rehabilitation exercise program, and 3) participants without hyperkyphosis solely undergoing cardiac rehabilitation exercise program. the groups will be evaluated based on measurements of kyphosis index, physical performance and spirometry at the beginning, after 6 weeks, and upon completion of the 12-week program.


Eligibility criteria:
inclusion criteria: * heart patients who will be admitted for cardiac rehabilitation at hadassah - mount scopus hospital * normal stress test results. * independent mobility. * stable hemodynamic and respiratory status. * ability to speak and read basic hebrewץ * ability to watch videos on a mobile phone or computer. * not receiving any other forms of physical therapy or physical treatment. exclusion criteria: * presence of unstable angina. * neurological disorders or mental illnesses that interfere with communication. * movement disorders due to neurological disease. * severe orthopedic limitations hindering the execution of motor exercises.

Keywords: home-based program graded exercise test spirometry flexicurve ruler six-minute walk test posture kyphosis index physical functional capacity tug test
a study of the effect of ce-224535 on knee oa (osteoarthritis) pain

Conditions: Osteoarthritis

Summary: ce-224535 is a new medication being developed as an analgesic and anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (oa). the purpose of this study is to evaluate the analgesic and anti inflammatory efficacy and safety of ce 224,535 versus placebo and naproxen treatment in patients with oa knee pain.


Eligibility criteria:
inclusion criteria: * is a healthy adult 18 to 75 years of age, inclusive, in general good health and with diagnosis of knee oa, as determined by the american college of rheumatology (acr) clinical/radiographic classification criteria for oa of the knee. * women must be of non childbearing potential (amenorrhea for at least 1 year plus have a serum follicle stimulating hormone (fsh) level \>30 iu/l, bilateral oophorectomy or hysterectomy), and have a confirmed negative serum pregnancy test at the screening visit prior to randomization. exclusion criteria: * history of other diseases that may involve the study joint, including inflammatory joint diseases, crystalline disease, endocrinopathies, metabolic diseases, infections, neuropathic disorders, avascular necrosis, paget's disease, or tumors. * women of childbearing potential, or who are pregnant or lactating.
optimization of guidance in a digital tool for problematic alcohol use

Conditions: Drinking Excessive

Summary: the purpose of the study is to evaluate the effects on alcohol consumption, and the consumption of time spent by a qualified clinician, by adding different forms of guidance to a digital intervention based on an alcohol diary and techniques from cognitive behavioral therapy and relapse prevention. the participants will be adults with problematic alcohol use. the trial will be a 2\*2 factorial experiment where written guidance and/or an extra mid-treatment telephone interview will be added to the basic digital intervention, by randomization. the randomized factorial experiment will create four equally large groups (1:1:1:1) who will receive different combinations of added guidance. main outcome will be effects on alcohol consumption. effects on alcohol consumption will also be combined with clinician time spent on guidance to assess the resource-effectiveness of added forms of guidance.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age 2. access to internet 3. ≥8 points for men and ≥6 points for women on alcohol use disorders identification test (audit) exclusion criteria: 1. insufficient knowledge of the swedish language 2. difficulties reading or writing related to a digital intervention. 3. other ongoing psychological treatment with a content similar to that in the current study (problematic alcohol use). 4. high suicide risk based on telephone assessment. 5. other urgent need for more intensive psychiatric care, or addiction care services, based on telephone assessment.
role of pacap in nehprotic syndrome

Conditions: Nephrotic Syndrome

Summary: this study will identify the role of pacap (pituitary adenylate cyclase-activating polypeptide) deficiency in patients with nephrotic syndrome. pacap is a neuropeptide that has a putative role as an inhibitor of megakaryopoiesis and platelet function. patients with nephrotic syndrome show decreased pacap plasma levels, due to urinary loss. we hypothesize that in severe nephrotic syndrome, plasma deficiency of pacap enhances megakaryopoiesis and causes blood platelet activation, which contribute to the increased rate of thromboembolic disease in these patients. to test our hypothesis, the role of pacap deficiency on pro-thrombotic state in patients with nephrotic syndrome will be studied using patient blood and urine samples.


Eligibility criteria:
inclusion criteria: * new patient with nephrotic syndrome of patient during relapse of nephrotic syndrome * under 16 years old * treatment for nephrotic syndrome not yet started by first sample collection exclusion criteria: * none

Keywords: pacap (pituitary adenylate cyclase-activating polypeptide) nephrotic syndrome thrombosis platelets
quality of life assessment in alzheimer's disease (ad) patients receiving aricept tablets

Conditions: Alzheimer Disease

Summary: this study assessed the hr qol (health related quality of life) of subjects with mild to moderate ad, who received aricept under usual clinical practice.

this non-interventional study enrolled patients with mild to moderate dementia of the alzheimer's type, who have been prescribed treatment with aricept under usual clinical practice.

Eligibility criteria:
inclusion criteria: * diagnosis of alzheimer's disease exclusion criteria: * there are no exclusion criteria

Keywords: non-interventional mild to moderate alzheimer's aricept.
transcranial electrical stimulation for management of orthostatic instability in acute cervical spinal cord injury

Conditions: Orthostatic Hypotension; Postural Hypotension

Summary: individuals with acute cervical spinal cord injury (sci) can suffer from an excessive and prolonged fall in blood pressure when assuming an upright position, such as transitioning from lying to sitting or standing, a condition also known as orthostatic hypotension (oh). due to a decrease in cerebral oxygenation, affected individuals can develop debilitating symptoms including lightheadedness, blurred vision, fatigue and even loss of consciousness. recent evidence suggests that oh has a negative impact on cognition in individuals with sci. clinical observations suggest that oh can lead to neurological deterioration in individuals who may otherwise have a stable sci. the presence of symptomatic oh prevented participation in 43% of physical therapy treatment sessions in a study of individuals with acute sci despite the use of current treatment options. oh is known to adversely affect health, delay rehabilitation and prolong hospitalization in the acute phase of management of individuals who display it. our team found oh was present in 41 of 55 (75%) patients with acute cervical sci at our center in 2004. we plan to research the efficacy of a low-cost, non-invasive device known as transcranial electrical stimulation (tes) to manage oh in individuals with acute cervical sci. previous studies have shown that this device is safe to use in individuals with sci, and has improved blood pressure control in non-sci individuals. we hypothesize that in individuals with acute cervical sci and oh, tes intervention will elicit an attenuation of the drop in systolic bp (sbp)in response to orthostatic stress. tes-induced differences will be most pronounced in those individuals with sparing of spinal autonomic pathways


Eligibility criteria:
inclusion criteria: * medically stable individuals with acute traumatic cervical sci with oh; * age 18-65 years; * able to give informed consent. oh will be defined as per the american academy of neurology consensus as a decrease in systolic bp ≥ 20 mmhg, or diastolic bp ≥ 10 mmhg when assuming an upright position on the sit-up test, whether or not symptoms occur. exclusion criteria: * individuals with: any clinically important or unstable medical or psychiatric disorders; * history of seizures; * neuropsychiatric comorbidity; * acute conditions that could exacerbate cardiovascular control, ie: untreated urinary tract or chest infections, open wounds, etc; * alterations in head computed tomography or head mri; * any cognitive dysfunction or language barrier that would prevent subjects from following english instructions. * use of short acting medications for oh (ie: midodrine) will not be a contra-indication as they will be withheld prior to testing, however having continuous administration of vasopressors will be an exclusion criteria.

Keywords: spinal cord injury cardiovascular orthostatic hypotension transcranial electrical stimulation electrotherapy
analysis of defocus curve of pre-presbyopic and emerging presbyopic patients

Conditions: Presbyopia

Summary: educating patients on visual performance with presbyopic correcting intraocular lenses is crucial. understanding the defocus curve of pre-presbyopic and emerging presbyopic crystalline lens will provide eye care provides useful information to better educate patients on visual performance expectations after cataract surgery with a presbyopic correcting intraocular lens. our objective will be to assess the subjective range of clear vision of a pre-presbyopic and emerging presbyopic patient population utilizing a defocus curve. a comparison of the pre-presbyopic and emerging presbyopic defocus curve to all fda-approved presbyopic intraocular lenses will be discussed in the manuscript.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide written informed consent on the irb approved informed consent form 2. 37-48 years of age 3. phakic exclusion criteria: 1. previous cataract surgery 2. any pathology for which, in the investigator's judgement, could reduce the subjects bcva 3. subjects that are unable to obtain 20/20 bcva (i.e. amblyopia, etc.)
corneal nerve structure in sjogren's

Conditions: Sjogren's Syndrome; Vitamin D Deficiency

Summary: patients who are suspected of or diagnosed with sjogren's disease will be evaluated for ocular symptoms and corneal nerve morphology. we are specifically interested in the relationship between vitamin d level and aberrations in the morphology of the corneal nerves.

patients with either suspected or confirmed diagnosis of sjogren's disease will be recruited to participate. participation will involve the completion of a brief survey (the osdi), corneal evaluation with an aesthesiometer, corneal staining with fluorescein and lissamine green, and finally measurement of tear-film breakup time. in addition, participants will have their corneal nerve morphology evaluated with the heidelberg confocal microscope and finally they will have a blood draw performed to assess vitamin d level.

Eligibility criteria:
inclusion criteria: * suspected or confirmed sjogren's syndrome * 18+ years of age exclusion criteria: * any condition that in the opinion of the investigator may confound study results or cause concerns for safety
vr mindfulness study

Conditions: Anxiety; Depression; Stress; Pain, Acute; Pain, Chronic

Summary: this is an exploratory study investigating the use of virtual reality-based guided mindfulness meditation in improving pain, stress, and mood within various clinical populations. the feasibility of utilizing vr applications within the populations of patients with various specific disease types and clinical settings is a burgeoning area of research. the goal is to establish an association between the use of vr-based mindfulness meditation, and pain, stress, and mood scores.

this is a two-center, multi-site exploratory study conducted within the university of california, los angeles health and greater los angeles va systems. a total of 60 subjects will be recruited. screening data will be reviewed to determine subject eligibility. subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. subjects will undergo assessments of stress, depression, anxiety, and pain at baseline, pre- and post-vr guided mediation, and monthly for three months. each subject can undergo vr-guided meditation session no more than one time per day. in subjects who are hospitalized, an attempt will be made to have the subjects undergo the vr meditation and complete the pre- and post- meditation assessments daily until hospital discharge. duration of the study is expected to be 1 year. each session is expected to last approximately 15 minutes. subjects will be given instructions on proper use of the vr devices and how to start the guided meditation software. once familiar with the device, participants will undergo a guided vr meditation using a commercial vr application. the meditation will last approximately 15 minutes. prior to starting and on upon completion of each vr meditation session, participants' state pain, anxiety, depression, and stress will be assessed. for each participant enrolled, baseline and monthly assessments using the dass-21 and ppi-sfi3a will be performed for three consecutive months

Eligibility criteria:
inclusion criteria: * adults at least 18 years old * able to read and understand english (guided meditation software has not yet been translated to languages other than english) exclusion criteria: * age \<18 years old * unable to speak, read or understand english language * blindness or severe hearing impairment * any disability or neurological deficit that would impair subject from using the virtual reality console * significant movement disorder * vertigo and/or motion sickness

Keywords: virtual reality anxiety depression pain mood mindfulness meditation
observational registry to assess the durability of effect of cxl in patients with corneal ectasia after refractive surgery

Conditions: Corneal Ectasia

Summary: the objectives of this post market registry are to evaluate the safety and durability of treatment effect up to 3 years following cross-linking performed with photrexa viscous (riboflavin 5'- phosphate in 20% dextran ophthalmic solution), photrexa (riboflavin 5'- phosphate ophthalmic solution), and the kxl system in patients with corneal ectasia following refractive surgery.

approximately 200 patients who are planning to undergo or have undergone cxl for the treatment of corneal ectasia following refractive surgery in one or both eyes according to the prescribing information in the photrexa viscous and photrexa package insert could be enrolled. patients will be followed for safety and effectiveness at months 3, 6, 12, 24 and 36 following cross-linking treatment.

Eligibility criteria:
inclusion criteria: 1. be at least 18 years of age, male or female, of any race; 2. provide written informed consent and sign a hipaa form; 3. willingness and ability to follow all instructions and comply with schedule for study visits; 4. have a diagnosis of corneal ectasia post-refractive surgery (such as lasik, prk); 5. planning to undergo (or have undergone within the past 90 days) corneal collagen cross-linking with photrexa viscous/ photrexa and the kxl system, per the prescribing information (note: complete treatment and follow-up data, including any product-related events at time of procedure through the time of enrollment must be available); 6. for females capable of becoming pregnant, agree to have urine pregnancy testing performed prior to enrolling in the registry; must not be pregnant or lactating. exclusion criteria: 1. if female, be pregnant, nursing, or have a positive urine pregnancy test prior to enrollment in the registry; 2. the investigator may exclude or discontinue any patient for any sound medical reason.
effect of rozerem on the perception of gerd symptoms in patients with chronic insomnia.

Conditions: Gastroesophageal Reflux Disease; Chronic Insomnia

Summary: to determine if administration of rozerem in comparison to a placebo reduces or eliminates gastroesophageal reflux disease(gerd) symptoms in individuals with both gerd and chronic insomnia.

this is a prospective, randomized, double-blind parallel group study comparing the effect of rozerem vs. placebo on gastroesophageal reflux disease(gerd) symptomatology as the primary outcome, and sleep quality and quality of life as secondary outcomes.

Eligibility criteria:
inclusion criteria: * stop h2 blockers 72 hrs prior to starting study * stop ppi - 3 weeks prior to staring study * heartburn 3+ times a week * insomnia 3+ times a week for 3 months * erosive esophagitis or abnormal ph test exclusion criteria: * on ppi or h2 blocker \& not willing to get off * normal egd (upper endoscopy) w/ normal ph test * upper endoscopy(egd)with erosive esophagitis(ee)- (la c\&d) la=los angeles criteria. grades include a-d * previous gastrointestinal surgery * hx of diabetes/neuropathy * hx of seizures * known psychological abnormalities(depression,anxiety...) * clinically significant underlying co morbidity * narcotic medications(pain meds) * regularly taking sleeping medications (2 week wash-out allowed) * taking medications that alter sleep-psychotropic's, antihistamines, narcotics and benzodiazepines sleep apnea or other sleep disorders-plm, rls etc.

Keywords: gerd insomnia acid reflux heartburn